1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. IMPEL PHARMACEUTICALS INC

Impel Pharmaceuticals Inc

XNAS: IMPL

Watchlist

Portfolio

Share


Insider Trading disclosures for Impel Pharmaceuticals Inc

The latest disclosure was made by David Allison in Impel Pharmaceuticals Inc where a trade of 13,222 Stock Option (right to buy) done was reported to US exchanges on June 16, 2023.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
David Allison Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2023 13,222 13,222 - - Stock Option (right to buy)
Darren S. Cline Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2023 13,222 13,222 - - Stock Option (right to buy)
Timothy S. Nelson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2023 13,222 13,222 - - Stock Option (right to buy)
Mahendra Gopaldas Shah Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2023 13,222 13,222 - - Stock Option (right to buy)
Diane E. Wilfong Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2023 13,222 13,222 - - Stock Option (right to buy)
Darren S. Cline Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 Apr 2023 20,013 20,013 - - Stock Option (right to buy)
Leonard S. Paolillo Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 Feb 2023 50,000 50,000 - - Stock Option (right to buy)
John Hoekman Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 Feb 2023 42,500 42,500 - - Stock Option (right to buy)
John H. Leaman Chief Fin. & Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 Feb 2023 70,000 70,000 - - Stock Option (right to buy)
Adrian Adams Director, COB, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 Feb 2023 200,000 200,000 - - Stock Option (right to buy)
John H. Leaman Chief Fin. & Business Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 31 Dec 2022 10,571 0 - - Restricted Stock Units (RSUs)
John H. Leaman Chief Fin. & Business Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 31 Dec 2022 10,571 10,571 - 0 Common Stock
John H. Leaman Chief Fin. & Business Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.75 per share. 31 Dec 2022 3,627 6,944 - 3.7 13,601 Common Stock
David Allison Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 12,789 12,789 - - Stock Option (right to buy)
Timothy S. Nelson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 12,789 12,789 - - Stock Option (right to buy)
Mahendra Gopaldas Shah Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 12,789 12,789 - - Stock Option (right to buy)
H. Stewart Parker Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 12,789 12,789 - - Stock Option (right to buy)
Diane E. Wilfong Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 16 Jun 2022 12,789 12,789 - - Stock Option (right to buy)
Stephen B. Shrewsbury Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 29 Mar 2022 24,606 0 - - Stock Option (right to buy)
Stephen B. Shrewsbury Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.97 per share. 29 Mar 2022 24,606 97,990 - 2.0 48,474 Common Stock
Leonard S. Paolillo Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2022 40,000 40,000 - - Stock Option (right to buy)
John Hoekman Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2022 35,000 35,000 - - Stock Option (right to buy)
John H. Leaman Chief Fin. & Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2022 100,000 100,000 - - Stock Option (right to buy)
Stephen B. Shrewsbury Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2022 30,000 30,000 - - Stock Option (right to buy)
Adrian Adams Director, COB, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 26 Jan 2022 175,000 175,000 - - Stock Option (right to buy)
John Hoekman Chief Scientific Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 22 Dec 2021 20,000 0 - - Stock Option (right to buy)
John Hoekman Chief Scientific Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.64 per share. 22 Dec 2021 20,000 128,221 - 1.6 32,800 Common Stock
Timothy S. Nelson Director Purchase of securities on an exchange or from another person at price $ 10.76 per share. 19 Nov 2021 10,000 10,000 - 10.8 107,554 Common Stock
John H. Leaman Chief Fin. & Business Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 19 Oct 2021 10,571 10,571 - - Restricted Stock Units (RSUs)
Stephen B. Shrewsbury Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.95 per share. 21 Sep 2021 53,954 73,384 - 2.9 159,164 Common Stock
Stephen B. Shrewsbury Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.97 per share. 21 Sep 2021 14,780 14,780 - 2.0 29,117 Common Stock
Stephen B. Shrewsbury Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.46 per share. 21 Sep 2021 4,650 19,430 - 2.5 11,439 Common Stock
Stephen B. Shrewsbury Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 21 Sep 2021 53,954 29,587 - - Stock Option (right to buy)
Stephen B. Shrewsbury Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 21 Sep 2021 4,650 541 - - Stock Option (right to buy)
Stephen B. Shrewsbury Chief Medical Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 21 Sep 2021 14,780 0 - - Stock Option (right to buy)
Adrian Adams Director, COB, CEO and President Purchase of securities on an exchange or from another person at price $ 15.89 per share. 18 Aug 2021 600 20,000 - 15.9 9,532 Common Stock
Adrian Adams Director, COB, CEO and President Purchase of securities on an exchange or from another person at price $ 13.81 per share. 18 Aug 2021 17,203 17,203 - 13.8 237,506 Common Stock
Adrian Adams Director, COB, CEO and President Purchase of securities on an exchange or from another person at price $ 14.91 per share. 18 Aug 2021 2,197 19,400 - 14.9 32,751 Common Stock
Adrian Adams Director, COB, CEO and President Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Jul 2021 50,000 50,000 - - Stock Option (right to buy)
Stephen B. Shrewsbury Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Jul 2021 50,000 50,000 - - Stock Option (right to buy)
John H. Leaman Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Jul 2021 50,000 50,000 - - Stock Option (right to buy)
John Hoekman Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Jul 2021 50,000 50,000 - - Stock Option (right to buy)
Leonard S. Paolillo Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 20 Jul 2021 30,000 30,000 - - Stock Option (right to buy)
Diane E. Wilfong Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jul 2021 11,500 11,500 - - Stock Option (right to buy)
H. Stewart Parker Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jul 2021 11,500 11,500 - - Stock Option (right to buy)
Mahendra Gopaldas Shah Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jul 2021 11,500 11,500 - - Stock Option (right to buy)
Timothy S. Nelson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jul 2021 11,500 11,500 - - Stock Option (right to buy)
David Allison Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Jul 2021 11,500 11,500 - - Stock Option (right to buy)
John Hoekman Chief Scientific Officer 27 Apr 2021 4,253 108,496 - 0 Common Stock
John Hoekman Chief Scientific Officer 27 Apr 2021 69,657 0 - - Series A-2 Preferred Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters